158 related articles for article (PubMed ID: 14986078)
1. Implications of dose rounding of chemotherapy to the nearest vial size.
Dooley MJ; Singh S; Michael M
Support Care Cancer; 2004 Sep; 12(9):653-6. PubMed ID: 14986078
[TBL] [Abstract][Full Text] [Related]
2. Rounding rituximab dose to nearest vial size.
Patel S; Le A
J Oncol Pharm Pract; 2013 Sep; 19(3):218-21. PubMed ID: 23114093
[TBL] [Abstract][Full Text] [Related]
3. Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.
Vandyke TH; Athmann PW; Ballmer CM; Kintzel PE
J Oncol Pharm Pract; 2017 Jul; 23(5):379-383. PubMed ID: 27000279
[TBL] [Abstract][Full Text] [Related]
4. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization.
Chillari KA; Southward J; Harrigan N
J Oncol Pharm Pract; 2018 Oct; 24(7):507-510. PubMed ID: 28732452
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
Lindsey S; Parsons LB; Figg LR; Rhodes J
J Oncol Pharm Pract; 2018 Jan; 24(1):47-55. PubMed ID: 29251257
[TBL] [Abstract][Full Text] [Related]
7. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
Moore DC; McVey GN
J Oncol Pharm Pract; 2018 Jan; 24(1):42-46. PubMed ID: 27760811
[TBL] [Abstract][Full Text] [Related]
8. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
Francis SM; Heyliger A; Miyares MA; Viera M
J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
[TBL] [Abstract][Full Text] [Related]
9. Financial Impact of an Automated Oncology Dose-Rounding Initiative: One-Year Analysis.
Dela-Pena JC; Eschenburg KA; LaRocca VW; Patel D; Hough SM
JCO Clin Cancer Inform; 2021 Aug; 5():805-810. PubMed ID: 34351786
[TBL] [Abstract][Full Text] [Related]
10. [Lower costs for anticancer drugs by safety margin around calculated dose and by fine-tuning on ampoule strength].
Mertens S; de Jongh FE
Ned Tijdschr Geneeskd; 2009; 153():B162. PubMed ID: 19785801
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution.
Graff JM; Cramer J; Kolb LL; Agherrabi Z; Burgess M
J Oncol Pharm Pract; 2024 Jun; 30(4):705-709. PubMed ID: 37350075
[TBL] [Abstract][Full Text] [Related]
12. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings.
Jarkowski A; Nestico JS; Vona KL; Khushalani NI
J Oncol Pharm Pract; 2014 Feb; 20(1):47-50. PubMed ID: 23512270
[TBL] [Abstract][Full Text] [Related]
13. Minimization of olaratumab drug waste using real-world data.
Sheffield KM; Beyrer JK; Watson IA; Stafford K; Mills BJ; Ale-Ali A
Am J Health Syst Pharm; 2017 Jun; 74(11):832-842. PubMed ID: 28461327
[TBL] [Abstract][Full Text] [Related]
14. Decreasing drug waste, reducing drug costs, and improving workflow efficiency through the implementation of automated chemotherapy dose rounding rules in the electronic health record system.
Shah V; Spence A; Bartels T; Betcher J; Soefje S
Am J Health Syst Pharm; 2022 Apr; 79(8):676-682. PubMed ID: 34940791
[TBL] [Abstract][Full Text] [Related]
15. Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology.
El Baraka S; Cherif Chefchaouni A; Bourdaime A; Ouedraogo JM; Shytry O; Belahcen MJ; Rahali Y
J Oncol Pharm Pract; 2023 Sep; ():10781552231203403. PubMed ID: 37728162
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study.
Yu JK; Iorio A; Chelle P; Edginton AN
Haemophilia; 2021 May; 27(3):358-365. PubMed ID: 33650745
[TBL] [Abstract][Full Text] [Related]
17. Cost savings from dose rounding of biologic anticancer agents in adults.
Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
[TBL] [Abstract][Full Text] [Related]
18. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.
Kouno T; Katsumata N; Mukai H; Ando M; Watanabe T
Jpn J Clin Oncol; 2003 Jun; 33(6):309-13. PubMed ID: 12913086
[TBL] [Abstract][Full Text] [Related]
19. APPROPRIATE DOSE ROUNDING OF CYTOKINE MODULATORS FOR PAEDIATRIC RHEUMATOLOGY INPATIENTS.
Paget C
Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540226
[TBL] [Abstract][Full Text] [Related]
20. Assessment of rabies immune globulin dose rounding at a university health system.
Acquisto NM; Uttaro E; Debona D; Minhaj FS
Am J Emerg Med; 2022 Aug; 58():141-147. PubMed ID: 35689960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
